A $2.1 billion funding round fuels Isomorphic Labs as it deploys its new Drug Design Engine. The Google DeepMind spinoff partnered with Novartis and Eli Lilly to find hidden drug targets. This approach leverages protein structure prediction to bypass traditional discovery bottlenecks. It moves AI-designed medicine closer to clinical reality.